BIOAF (Bioasis Technologies) Other Long-Term Liabilities: $0.11 Mil (As of Nov. 2022)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BIOAF Bioasis Technologies Inc BIOAF
12 GF Score
Price $0.00
View Full Analysis

What is Bioasis Technologies Other Long-Term Liabilities?

Bioasis Technologies BIOAF 12 Other Long-Term Liabilities is $0.11 Mil as of Nov. 2022. GuruFocus rates BIOAF with a GF Score™ of 12/100.

Bioasis Technologies's other long-term liabilities for the quarter that ended in Nov. 2022 was $0.11 Mil.

Bioasis Technologies's quarterly other long-term liabilities declined from May. 2022 ($0.11 Mil) to Aug. 2022 ($0.07 Mil) but then increased from Aug. 2022 ($0.07 Mil) to Nov. 2022 ($0.11 Mil).

Bioasis Technologies's annual other long-term liabilities increased from Feb. 2020 ($0.33 Mil) to Feb. 2021 ($0.72 Mil) but then declined from Feb. 2021 ($0.72 Mil) to Feb. 2022 ($0.62 Mil).

Bioasis Technologies Other Long-Term Liabilities Related Terms

Bioasis Technologies Other Long-Term Liabilities Historical Data

* Premium members only.

The historical data trend for Bioasis Technologies's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bioasis Technologies Other Long-Term Liabilities Chart

Bioasis Technologies Annual Data
Trend Feb13 Feb14 Feb15 Feb16 Feb17 Feb18 Feb19 Feb20 Feb21 Feb22
Other Long-Term Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.78 0.33 0.72 0.62

Bioasis Technologies Quarterly Data
Feb18 May18 Aug18 Nov18 Feb19 May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22
Other Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.05 0.62 0.11 0.07 0.11
BIOAF
12GF Score
Bioasis Technologies Inc BIOAF
Other Long-Term Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bioasis Technologies Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

What does a Other Long-Term Liabilities of $0.11 Mil mean?
Bioasis Technologies (BIOAF) has a Other Long-Term Liabilities of $0.11 Mil as of Nov. 2022. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Bioasis Technologies and its competitors.
Is Bioasis Technologies' Other Long-Term Liabilities too high?
Bioasis Technologies' current Other Long-Term Liabilities is $0.11 Mil. Overall, Bioasis Technologies has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Bioasis Technologies' Other Long-Term Liabilities compare to VRTX and REGN?
Bioasis Technologies' Other Long-Term Liabilities of $0.11 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long-Term Liabilities for a Biotechnology company?
A good Other Long-Term Liabilities depends on the Biotechnology industry context. However, Other Long-Term Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long-Term Liabilities mean?
A high Other Long-Term Liabilities can signal that a stock is expensive relative to its fundamentals. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Bioasis Technologies and its competitors. Bioasis Technologies's current Other Long-Term Liabilities is $0.11 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioasis Technologies stock overvalued right now?
Bioasis Technologies (BIOAF) has a current Other Long-Term Liabilities of $0.11 Mil. The current Other Long-Term Liabilities is $0.11 Mil. Bioasis Technologies' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long-Term Liabilities calculated?
Other Long-Term Liabilities is calculated from a company's financial statements. For Bioasis Technologies (BIOAF), the current Other Long-Term Liabilities is $0.11 Mil as of Nov. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Bioasis Technologies Business Description

Address 157 Church Street, 19th Floor, New Haven, CT, USA, 06510
Bioasis Technologies Inc is a development stage biopharmaceutical company engaged in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. The company's xB3 program describes its proprietary carrier, p97, and components thereof, to deliver therapeutics across the blood-brain barrier (BBB).
12GF Score

Get the complete analysis for BIOAF

Other Long-Term Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price